Korea Stock Market Insights

Tag: Bio

JS Link After-Hours Trading Deep Dive: Opportunity or Red Flag?
JS Link Stock Sees After-Hours Trading Surge: Should You Invest Now?
The after-hours trading event involving JS Link on September 11, 2025, has caught the attention of investors. What does the significant sell-off by institutional investors signify? This article provides an in-depth analysis of the event, exploring its background and offering insights into future investment strategies. We delve into the company’s business diversification, financial status, and market conditions to offer key information for informed investment decisions.
What Happened? JS Link After-Hours Trading Analysis
After the market closed on September 11, 2025, JS Link experienced a significant after-hours trading event with a volume of 437,987 shares, totaling approximately 7.8 billion KRW. Notably, institutional investors sold off around 5.6 billion KRW worth of shares, while foreign investors bought approximately 580 million KRW. This represents about 1.5% of the company’s market capitalization (520.4 billion KRW), which might not significantly impact short-term stock prices. However, after-hours trading often reflects crucial information, warranting further analysis of its underlying causes.
Why Did It Happen? Fundamental and Financial Analysis
JS Link is pursuing business diversification, shifting from its existing bio and healthcare business to permanent magnets and rare earth magnet recycling. While this diversification strategy appears positive for long-term growth, the company’s financial status, as of the 2024 business report, raises concerns. With retained earnings showing a deficit of 86.2 billion KRW and an operating loss of 9.1 billion KRW, the financial burden of investments in new businesses is a significant risk. This financial difficulty could be linked to the substantial sell-off by institutional investors. Furthermore, the current order backlog of 7.2 billion KRW, while contributing to short-term sales, remains insufficient considering the expected contribution from the new business segments.
What’s the Investment Strategy? Market Context and Recommendations
Recent macroeconomic indicators, such as exchange rates, interest rates, and oil prices, have remained relatively stable. However, the volatility of exchange rates remains a concern, particularly given the new business’s reliance on raw material imports. In the short term, investors should observe the market’s reaction to the sell-off and seek further information regarding the motivations behind it. A long-term strategy requires close monitoring of the new business’s performance, the improvement of profitability in existing segments, and the company’s efforts to strengthen its financial health.
Key Action Plan for Investors
- Short-term: Verify the reasons behind the after-hours trading and monitor stock price trends.
- Long-term: Monitor the progress of new business ventures, profitability of existing business, and efforts to improve the financial structure.
Frequently Asked Questions
What are JS Link’s main businesses?
JS Link is diversifying its business portfolio beyond its existing bio and healthcare operations to include permanent magnets and rare earth magnet recycling.
Who were the main parties involved in the after-hours trading?
Institutional investors sold a large volume of shares (approx. 5.6 billion KRW), while foreign investors purchased a smaller amount (approx. 580 million KRW).
What is the current state of JS Link’s financials?
As of 2024, JS Link reported a deficit in retained earnings of 86.2 billion KRW and an operating loss of 9.1 billion KRW. Improving the financial situation is crucial.
What should investors be cautious of?
While the business diversification holds growth potential, investors should exercise caution considering the current financial difficulties and the reasons behind the large sell-off in after-hours trading.
09/11/2025
Cytogen Announces Treasury Stock Disposal: Impact on Stock Price and Investment Strategy
Cytogen has announced the disposal of 60,000 treasury stocks. Is this simply employee compensation, or is there a hidden meaning? This article analyzes the impact of Cytogen’s treasury stock disposal decision on its stock price and fundamentals, and highlights key points for investors to consider. Find out now!
Cytogen Disposes of 60,000 Treasury Stocks: What’s Happening?

On September 10, 2025, Cytogen announced the disposal of 60,000 common stocks (approximately ₩200 million) for employee compensation. The disposed shares represent only 0.26% of the total outstanding shares.

How Will This Decision Impact Cytogen?

Positive impacts include boosting employee morale and motivation, and the minimal dilution effect on stock price. However, the limited momentum for stock price increase, the limited impact on financial status, and the lack of direct correlation with fundamental improvements are factors to consider.

What Should Investors Focus On?
- Commercialization of Liquid Biopsy technology and overseas market expansion performance
- Continuous efforts to achieve operating profit and improve financial soundness
- Changes in employee performance after treasury stock distribution
Conclusion: Neutral Impact, Long-Term Perspective Needed

This treasury stock disposal is expected to have a neutral impact on Cytogen’s fundamentals. Investors should focus on the company’s long-term fundamental changes rather than short-term stock price fluctuations.
FAQ

What is the purpose of Cytogen’s treasury stock disposal?
It’s for employee compensation and motivation.
Will this treasury stock disposal significantly impact the stock price?
The impact on the stock price is expected to be limited due to the small number of shares.
What should investors pay attention to?
Investors should focus on the commercialization of the company’s core technology, overseas market expansion, and improvements in financial soundness.
09/11/2025
Paratekxis Korea (formerly BridgeBio Therapeutics) Stock Forecast: Is Digital Asset Venture a Key to Overcoming Crisis?
BridgeBio Therapeutics, once a promising innovative drug development company, has changed its name to Paratekxis Korea and announced its entry into the digital asset business. Facing uncertainties in clinical trial results for its core pipeline and continuous losses, Paratekxis Korea has chosen a bold transformation. What does the future hold for this company? This article analyzes Paratekxis Korea’s current situation and provides insights into investment strategies.
What Happened?

BridgeBio Therapeutics changed its name to Paratekxis Korea in August 2025 and added a digital asset business to its portfolio. The CEO was also replaced. These changes come amidst a challenging business environment, including uncertain Phase 2 clinical trial results for its key pipeline, BBT-877, and six consecutive years of net losses.

Why This Change?

The continuous losses and uncertainty surrounding the core pipeline threatened the company’s very existence. The move into the digital asset business appears to be a bold decision aimed at reducing the uncertainties of new drug development and securing new growth engines. The company is preparing for this transformation by securing funds through rights offerings and convertible bond issuances.

What’s Next?

While venturing into the digital asset business opens up new growth possibilities, it also increases uncertainty. The company’s future hinges on the development progress of its existing pipeline (BBT-207, BBT-301, BBT-401, etc.), the concrete plans for its digital asset business, and its performance. Predicting success at this stage is difficult.

What Should Investors Do?
- Cautious Approach: Before making any investment decisions, carefully analyze the pipeline’s development status, fundraising capabilities, and the digital asset business plan.
- Information Gathering: Continuously monitor the company’s IR activities and public disclosures to stay updated.
- Market Monitoring: Pay close attention to the overall investment sentiment in the bio sector, interest rates, exchange rate fluctuations, and other macroeconomic and industry trends.
FAQ

What are Paratekxis Korea’s main pipelines?

They include BBT-207, BBT-877, BBT-301, and BBT-401. BBT-877, a candidate for idiopathic pulmonary fibrosis, held high expectations, but there are uncertainties regarding its phase 2 clinical trial results.

Why did Paratekxis Korea enter the digital asset business?

This is interpreted as a strategy to mitigate the uncertainties of the existing new drug development business and secure new growth engines. It appears to be an attempt to overcome continuous net losses and uncertainties surrounding clinical trial results of the core pipeline.

Should I invest in Paratekxis Korea?

The company presents both high growth potential and significant risk factors. Investments should be approached with caution, and decisions should be made after carefully analyzing the pipeline’s development progress, fundraising capabilities, and the digital asset business plan. This analysis is not investment advice, and the responsibility for investment lies with the individual investor.
09/11/2025
Samsung C&T IR Analysis: September 9th Conference – Key Takeaways for Investors

Samsung C&T Engages Global Investors

On September 9th, Samsung C&T will hold an Investor Relations (IR) session at an overseas conference. What does this mean for the company, which has shown stable growth with a diversified portfolio across construction, trading, bio, and other sectors? This article analyzes the key takeaways from the IR, market expectations, and the crucial points investors should focus on.

IR Event Analysis: What to Expect

Samsung C&T will provide updates on key management issues and hold a Q&A session. Following the recent amendment to their business report emphasizing transparency, detailed information on overseas construction projects and the future value of their bio business is anticipated.

Market Expectations and Fundamental Analysis

The market expects positive updates on Samsung C&T’s future growth strategy, especially their global expansion plans. Fundamentally, the company has a stable revenue structure thanks to its diversified portfolio, with the bio division seen as a key growth driver. The recent business report amendment, enhancing transparency, is viewed positively.

Macroeconomic Environment: Opportunities and Threats

The current rise in the KRW/USD exchange rate could benefit overseas earnings but may also increase cost burdens. Fluctuations in international gold and crude oil prices could impact their trading division. While decreasing interest rates in the US, Korea, and Europe are favorable for financing, inflationary pressures remain. These macroeconomic factors will play a crucial role in investment decisions.

Investment Strategy: Action Plan Post-IR

This IR presents an opportunity to reassess Samsung C&T’s investment appeal. Investors should carefully analyze the management updates and future outlook presented after the IR, considering market reactions and expert evaluations. Pay close attention to information on new pipelines in the bio business, and investments in new businesses like eco-friendly energy and smart cities.

What are Samsung C&T’s main businesses?

Samsung C&T operates a diverse range of businesses, including construction, trading, fashion, resorts, food & material distribution, and bio.

What are the key takeaways of this IR?

The company will share updates on its recent performance, future growth strategies, and global expansion plans through presentations and Q&A sessions.

What should investors be aware of?

Consider not just the IR information but also global macroeconomic uncertainties and potential volatility in the progress of construction projects.

09/08/2025
DT&CRO Secures $2.6M Government Contract: Investment Opportunity?
DT&CRO’s recent $2.6 million contract with the Incheon Regional Public Procurement Service is significant news for investors. This article provides a detailed analysis of the contract’s implications for DT&CRO’s future, from its contents to investment perspectives.
What Happened?
DT&CRO signed a contract worth $2.6 million with the Incheon Regional Public Procurement Service for the ‘Production of Chemical Hazard Test Data in 2025.’ This represents approximately 9.7% of DT&CRO’s revenue for the first half of 2025. The contract period runs from September 5, 2025, to October 30, 2026.
Why is This Contract Important?
This contract signifies more than just a new order. Currently, DT&CRO is facing profitability challenges due to investments in its PK/PD center. This government contract can contribute to improving the company’s financial structure by securing stable revenue. Strengthening its safety testing division will play a crucial role in solidifying its position as a full-service CRO.
What’s Next?
- Positive Outlook:
  Revenue growth and business stability
  Enhanced competitiveness in safety testing
  Acceleration of full-service CRO strategy
- Risk Factors:
  Uncertainty regarding profitability improvement
  Continued high debt ratio
  Intensifying competition in the CRO market
What Should Investors Do?
While this contract is a positive sign for DT&CRO, investors should exercise caution. Don’t focus solely on the short-term revenue increase. Carefully examine the company’s long-term profitability improvement potential and its ability to secure financial soundness. Paying close attention to future earnings announcements and management’s business strategies is crucial.
FAQ
What is the size of this contract?
$2.6 million, which represents approximately 9.7% of DT&CRO’s revenue for the first half of 2025.
Who is the counterparty to the contract?
The Incheon Regional Public Procurement Service.
Will this contract help improve DT&CRO’s profitability?
It has the potential to help, but it’s not certain. Cost management during contract execution will be critical, and addressing the company’s fundamental profitability issues will require additional efforts.
What should investors be cautious about?
Investors should not only consider the short-term revenue increase but also thoroughly evaluate the company’s long-term profitability improvement potential and its ability to achieve financial soundness.
09/07/2025
ISU Abxis IR Analysis: Investment Opportunity or Risk?
ISU Abxis held an Investor Relations (IR) session on September 9, 2025. Gaining attention alongside the growth of the rare disease treatment market, what message did ISU Abxis deliver to investors through this IR? This article analyzes the key takeaways from the IR, provides a future stock price outlook, and highlights the key points investors should consider.
1. ISU Abxis IR: What Was Discussed?

ISU Abxis held an investor relations (IR) session on September 9, 2025, presenting the company’s current status and future strategies. Key topics included the stable growth of its existing pharmaceutical business, updates on its new drug pipeline development, and diversification strategy through new business ventures.

2. Why It Matters: Investment Opportunities vs. Risk Factors
- Opportunities: High growth potential of the rare disease treatment market, commercialization potential of the new drug pipeline, securing growth engines through business diversification.
- Risks: Uncertainties surrounding new business ventures, potential failure in new drug development, and potential equity dilution due to convertible bond issuance.
3. What’s Next?: Future Stock Price Outlook

Considering the information released during the IR and the current market conditions, ISU Abxis’s stock price is expected to experience increased volatility. The stock price is likely to react sensitively, particularly to news related to new drug development and new business ventures. The possibility of stock dilution due to convertible bond issuance is also a factor that investors should closely monitor.

4. Investor Action Plan: What Should You Do?

Investors should thoroughly analyze the IR materials and make investment decisions based on a comprehensive assessment of the company’s long-term growth potential and risk factors. Continuous monitoring of the progress of the new drug pipeline, concrete results of new businesses, and resolution of uncertainties related to convertible bonds are particularly crucial.
Frequently Asked Questions (FAQ)

What are ISU Abxis’s main businesses?

ISU Abxis focuses on rare disease treatments and antibody therapeutics, while pursuing diversification through new ventures in health foods, real estate, and investment businesses.

What is the current status of ISU Abxis’s new drug development?

ISU Abxis possesses multiple drug pipelines and is actively engaged in research and development activities. Notably, they have confirmed the potential for monetization through technology transfer of ISU104.

How does the issuance of convertible bonds affect the stock price?

The issuance of convertible bonds carries the potential for equity dilution, which can put downward pressure on the stock price.
09/07/2025
Daewoong’s Fexuclue Approved in China: Investment Analysis and Future Outlook
Daewoong Pharmaceutical’s new drug for gastroesophageal reflux disease, Fexuclue, has officially entered the Chinese market! On September 2, 2025, Fexuclue obtained marketing authorization from the National Medical Products Administration (NMPA) of China. What impact will this achievement have on Daewoong’s future? In this article, we analyze the significance of Fexuclue’s entry into China and its impact on investors, and provide future prospects.
What Happened?

Daewoong Pharmaceutical’s ‘Fexuclue 40mg’, a treatment for gastroesophageal reflux disease (GERD), has received marketing authorization from China’s NMPA. This marks the first case of a Korean P-CAB-based new drug entering the Chinese market.

Why is it Important?

China is one of the largest pharmaceutical markets in the world. Fexuclue’s entry into China is expected to significantly contribute to Daewoong’s sales growth and profitability improvement. It will also demonstrate Daewoong’s new drug development capabilities and positively impact the company’s image.
- Sales Growth and Profitability Improvement: Expected explosive sales growth due to entry into a huge market.
- Strengthened New Drug Development Capabilities and Increased Pipeline Value: Demonstrates global competitiveness, positively impacting future drug development.
- Enhanced Corporate Image and Brand Value: Improves brand image as a successful overseas case of a domestic new drug.
What’s Next?

Daewoong is expected to focus on building local partnerships and establishing marketing strategies for successful market entry in China. A customized strategy considering the unique characteristics of the Chinese market is necessary, and efforts should be focused on securing market share through differentiation from competing products.

What Should Investors Do?

This marketing authorization is a positive signal, demonstrating Daewoong’s long-term growth potential. However, it may take time for actual sales to materialize, and there are risk factors such as market competition and regulatory changes. Therefore, it’s crucial for investors to closely monitor Daewoong’s China market entry strategy and performance trends before making investment decisions.
Frequently Asked Questions

What is Fexuclue?

Fexuclue is a new P-CAB-based drug used to treat gastroesophageal reflux disease (GERD). It shows faster onset of action and superior efficacy compared to existing PPI drugs.

What is the significance of obtaining marketing authorization in China?

China has a huge pharmaceutical market. Obtaining marketing authorization for Fexuclue in China is a significant step for Daewoong in increasing sales and expanding its global market.

What should investors be aware of?

It may take time for actual sales to materialize. It’s important to consider China’s competitive landscape and regulatory changes when making investment decisions.
09/05/2025
Daewoong Pharmaceutical’s Fexuclue Approved in China: Investment Outlook (September 2025)
Daewoong Pharmaceutical Sets Sights on the Chinese Market with Fexuclue

Daewoong Pharmaceutical’s novel gastroesophageal reflux disease treatment, Fexuclue, has received marketing authorization in China. This achievement signifies more than just an approval; it represents a pivotal entry point into the vast Chinese pharmaceutical market. This analysis will delve into the implications of Fexuclue’s entry into China for Daewoong, combined with an analysis of its 2024 business report, providing key insights and action plans for investors.
1. What Happened?

Daewoong Pharmaceutical’s Fexuclue has been granted marketing authorization by the National Medical Products Administration (NMPA) of China. While the company also released its 2024 business report (amended), the amendments primarily clarified existing information, with minimal direct impact on fundamentals.

2. Why Does It Matter?

China represents the second largest pharmaceutical market globally. Fexuclue’s entry into China presents a significant opportunity for Daewoong to boost sales and expand its global presence. As a P-CAB inhibitor with superior efficacy compared to existing PPIs, Fexuclue is expected to offer a new treatment option for Chinese patients suffering from gastroesophageal reflux disease. This also validates Daewoong’s R&D capabilities and could pave the way for further expansion into other global markets.

3. What’s Next?

Positive Scenario: If Fexuclue successfully establishes itself in the Chinese market, Daewoong’s sales and operating profit are likely to experience substantial growth. This could serve as a powerful catalyst for a rise in stock price.
- Short-term: Positive investor sentiment and stock price appreciation are anticipated.
- Long-term: Transformation into a global pharmaceutical company and increased corporate value are expected.
Considerations: Potential risk factors include intensified competition within the Chinese market, changes in local regulations, and the effectiveness of Daewoong’s marketing strategies. Fluctuations in exchange rates and rising interest rates are also factors to consider.

4. What Should Investors Do?

While Fexuclue’s entry into China is positive, investors should carefully consider the following factors before making investment decisions:
- Fexuclue’s sales performance and market share trends in China
- Competitive landscape and Daewoong’s marketing strategies
- Global market expansion strategy and the progress of R&D pipelines
- Impact of changes in the macroeconomic environment
Thorough analysis is crucial for identifying investment opportunities and managing risks.
Frequently Asked Questions

When will Fexuclue be launched in China?

The exact launch date has not yet been announced. Investors should monitor relevant news and official announcements from Daewoong Pharmaceutical.

How much is Fexuclue expected to sell in China?

Considering the market size and Fexuclue’s efficacy, substantial sales are expected. However, precise predictions are difficult due to various factors such as competition and marketing strategies.

How will Fexuclue’s entry into China affect the stock price?

While a positive short-term impact is likely, the long-term stock price trend will depend on Fexuclue’s actual sales performance, the success of the global market expansion strategy, and changes in the macroeconomic environment.
09/05/2025
GI Innovation Stock Forecast: Special Relationship Shareholder Changes and Investment Strategies
Are you considering investing in GI Innovation? Recent news of changes in special relationship shareholder stakes has stirred the market. This article provides a detailed analysis of the report released on September 4, 2025, offering insights into GI Innovation’s fundamentals, stock forecast, and investment strategies. Get the key information you need to make informed investment decisions amidst fluctuating market sentiment.
What Happened? Changes in GI Innovation’s Special Relationship Shareholder Stakes
According to the ‘Report on the Status of Large-volume Holdings of Stocks, etc.’ released on September 4, 2025, the stake held by CEO Myung-Ho Jang and other special relationship shareholders decreased from 29.91% to 27.99%. DS Asset Management, Anda Asset Management, and others reduced their stakes through market sales, while Brain Asset Management’s stake changed due to the dissolution of a special relationship related to convertible preferred stock.
Why Are These Changes Important?
Changes in special relationship shareholder stakes can impact market confidence in a company’s management stability and future direction. While this stake decrease may put short-term pressure on the stock price, the remaining stake is sufficient for maintaining management control.
So, What Does the Future Hold for GI Innovation?
Positive Factors: A robust R&D pipeline, successful technology transfers, and improved financial structure underpin GI Innovation’s long-term growth potential. Diverse pipelines, including immuno-oncology drugs (GI-101/GI-102), allergy treatments (GI-301), and metabolic immuno-oncology drugs (GI-108), will serve as future growth drivers.
Negative Factors: The sale of shares by special relationship shareholders may cause short-term stock price volatility. The inherent high failure rate of new drug development, financial burden from continuous R&D investment, and intensifying market competition are also risk factors to consider.
What Should Investors Do? Action Plan
- Monitor Pipeline Clinical Trial Results: Clinical trial results significantly impact stock prices, requiring continuous attention.
- Check for New Technology Transfer Agreements: Additional technology transfer agreements are a crucial indicator of the company’s growth potential.
- Understand Funding Plans: Investors should assess the company’s funding plans and execution capabilities for R&D investments.
- Observe Shareholder Movement Trends: Changes in major shareholder stakes can influence market sentiment.
- Consider Macroeconomic Factors: Interest rates, exchange rates, and bio-industry trends should be factored into investment decisions.
GI Innovation holds high growth potential, but investment always carries risk. Consider the action plan above to make informed investment decisions.
FAQ
What are GI Innovation’s main pipelines?
GI Innovation has a diverse pipeline including immuno-oncology drugs (GI-101/GI-102), allergy treatments (GI-301), and metabolic immuno-oncology drugs (GI-108).
How do special relationship shareholder changes affect the stock price?
In the short term, it can act as selling pressure, leading to a decline in stock price. However, the long-term impact depends on the company’s fundamentals and future outlook.
What should investors be aware of when investing in GI Innovation?
Investors should consider the high failure rate of new drug development, the financial burden from continuous R&D investment, and intensifying market competition. It’s also crucial to monitor clinical trial results, technology transfer agreements, and funding plans.
09/04/2025
Neurophet Stock Forecast: SBI Divestment – Setback or Opportunity? | Analyzing the Growth Potential of Brain Disease AI Solutions
SBI Divests Neurophet Shares: Setback or Opportunity?
On September 4, 2025, Neurophet’s major shareholder, SBI Investment, sold off a portion of its stake. How will this news affect Neurophet’s stock price? Is it a short-term setback or a long-term growth opportunity? This article provides a thorough analysis of the background of the SBI divestment, Neurophet’s fundamentals, and future investment strategies.
SBI Investment Divests Neurophet Shares – What Happened?

SBI Investment sold 93,715 shares of Neurophet on September 4, 2025, reducing its stake from 5.01% to 4.22%. The reason for the sale was stated as ‘KOSDAQ market sale,’ and it was carried out through the 2019 SBI Job Creation Fund, 2020 SBI Scale-up Fund, and SBI-KIS 2019 BIC Investment Association.

Why is the SBI Divestment Important? – Analyzing the Hidden Meaning

As a venture capital (VC) firm, SBI Investment’s primary goal is to recoup its investments. Therefore, this divestment is likely part of an investment recovery strategy rather than a negative assessment of Neurophet’s growth potential. However, the sale of shares by a major shareholder in the early stages of listing can negatively impact investor sentiment. Short-term downward pressure on the stock price seems inevitable.

So, What Happens to Neurophet? – Analyzing Fundamentals and Growth Potential
- Strengths: Neurophet has secured unique technology and a high market share in the brain image analysis software market. Notably, ‘Neurophet AQUA’ holds a monopoly in the domestic multiple sclerosis analysis market, and ‘Neurophet SCALE PET’ accounts for about 40% of the domestic PET image analysis software market.
- Opportunities: The medical AI market is expected to show high growth rates due to the aging population and the growth of the digital healthcare market. Neurophet is accelerating its entry into the global market in line with these market trends.
- Weaknesses: As of the first half of 2025, Neurophet recorded operating losses and net losses due to high R&D expenses. Improvement in financial structure is necessary.
- Threats: As a newly listed company, Neurophet’s stock price is highly volatile, and the SBI Investment’s divestment may cause a short-term drop in stock price.
What Should Investors Do? – Suggesting an Action Plan
- Short-term investors: Invest cautiously considering the possibility of a short-term stock price decline.
- Long-term investors: If you focus on Neurophet’s long-term growth potential, you can use the stock price drop as a buying opportunity. However, it is necessary to continuously monitor factors such as earnings improvement trends, new technology development, and global market entry performance.
Frequently Asked Questions (FAQ)

Is SBI’s divestment of Neurophet shares a negative sign for Neurophet’s future?

Since SBI’s main purpose as a venture capital firm is to recoup its investments, this sale is unlikely to be interpreted as a negative judgment on Neurophet’s future. It can be seen as a strategy to secure funds for the next stage of investment after recovering the initial investment.

Is it okay to invest in Neurophet?

Neurophet possesses excellent technology in the field of brain disease AI solutions and has high growth potential. However, since it is a newly listed company, investment involves risks, so sufficient analysis and information gathering are required before making investment decisions.

What is the outlook for Neurophet’s stock price?

In the short term, stock price volatility may increase due to SBI’s divestment, but in the long term, Neurophet’s growth is expected along with the growth of the brain disease AI solution market.
09/04/2025